Latest News and Press Releases

Basel, Switzerland, Feb. 03, 2005 (PRIMEZONE) -- Conference Call, 3rd February 2005, 4 p.m. CET (10 a.m. EST) Basilea Enters a Global Collaboration with Johnson & Johnson on Ceftobiprole. Dear...

BASEL, Switzerland, Jan. 4, 2005 (PRIMEZONE) -- Basilea Pharmaceutica AG announces the start of its phase II program for BAL8557 in oesophageal candidiasis. BAL8557 is a novel anti-fungal intended...

BASEL, Switzerland, Dec. 15, 2004 (PRIMEZONE) -- The U.S. Federal Trade Commission recently announced that it granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust...

BASEL, Switzerland, Nov. 4, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG announces the start of its international phase III program for ceftobiprole (BAL5788), a novel broad spectrum, first-in-class...

BASEL, Switzerland, Nov. 2, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG presents sixteen posters at the 44th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in...

BASEL, Switzerland, Oct. 28, 2004 (PRIMEZONE) -- Basilea announced today the enrolment of the first patients into its phase III program investigating the efficacy and safety of BAL4079 (alitretinoin)...

BASEL, Switzerland, Aug. 25, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG reported today its Interim Results for the first-half of 2004 that include funds raised in the company's Initial Public...

BASEL, Switzerland, June 30, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG announced today that it will receive funding as part of a European Commission programme for developing novel antibiotics...

BASEL, Switzerland, June 21, 2004 (PRIMEZONE) -- Basilea Pharmaceutica announced today that it has appointed Rienk Pypstra MD as Chief Development Officer. Dr. Pypstra, who has served as Basilea's...

BASEL, Switzerland, June 16, 2004 (PRIMEZONE) -- Basilea Pharmaceutica AG announced today that it received a second fast track designation from the U.S. Food and Drug Administration (FDA) for its...